TLDR Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
A 56-year-old man with alopecia areata (AA) and immune thrombocytopenia (ITP) experienced significant hair regrowth and normalized platelet counts after 14 months of treatment with baricitinib, an oral Janus kinase inhibitor. This case suggests a potential autoimmune link between AA and ITP and indicates that baricitinib could be an effective treatment for both conditions, though regular platelet monitoring and collaboration with hematology specialists are necessary. Further large-scale studies are required to confirm the safety and efficacy of baricitinib for ITP management.
July 2024 in “The Journal of Dermatology” A rare case shows alopecia areata and ITP occurring together, needing more research.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
148 citations,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
[object Object] 
184 citations,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
701 citations,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
5 citations,
January 1999 in “Pediatric Dermatology” A young girl had both alopecia areata and immune thrombocytopenic purpura at the same time, suggesting a possible link between the two.
April 2019 in “International journal of research in dermatology” A child with rough nails also had hair loss and allergies.
[object Object]
